Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS) is set to release its fourth quarter and full year 2023 financial results on February 21, 2024. The company, focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases, will host a conference call and webcast to discuss the results. The live webcast link will be available on the company's website, and a replay will be archived afterward.

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 21, 2024.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131248268/en/

Chris Lewis

Vice President, Investor Relations and Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation

FAQ

When will Glaukos Corporation release its fourth quarter and full year 2023 financial results?

Glaukos Corporation will release its fourth quarter and full year 2023 financial results after the market close on February 21, 2024.

What is the focus of Glaukos Corporation's medical technology and pharmaceutical products?

Glaukos Corporation focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

How can I participate in the conference call and webcast to discuss the financial results?

To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. The live webcast link will be available on the company's website at http://investors.glaukos.com.

Where can I find the replay of the conference call?

A replay of the conference call will be archived on the company's website following completion of the call.